|Articles|March 16, 2021
Supplements and Featured Publications
- Evolving Knowledge of the Unmet Needs in Dry Eye Disease
- Volume 27
- Issue 2
Participating Faculty for Evolving Knowledge of the Unmet Needs in Dry Eye Disease
Advertisement
Faculty
Jeffrey D. Dunn, PharmD, MBA
Vice President (previously)
Clinical Strategy and Programs and Industry Relations
Magellan Rx
Salt Lake City, Utah
Paul M. Karpecki, OD
DirectorCornea and External Disease
Kentucky Eye Institute
Lexington, Kentucky
Kentucky Eye Institute
Lexington, Kentucky
Associate Professor
Kentucky College of Optometry
University of Pikeville
Pikeville, Kentucky
Kentucky College of Optometry
University of Pikeville
Pikeville, Kentucky
Mary Elizabeth Meske, PharmD, RPh
Manager, Clinical Pharmacy
Senior Clinical Account Executive
National Health Plan/Pharmacy Benefit Manager
Deborah Reissman, PharmD
Managed Care Pharmacy Consultant
San Marcos, California
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
Paul M. Karpecki, OD
CONSULTANT OR PAID ADVISORY BOARD MEMBER:
AbbVie Inc; Bausch + Lomb Inc; Kala Pharmaceuticals; Novartis; Oyster Point Pharma, Inc; Sun Pharmaceutical Industries Ltd
LECTURE FEES:
Bausch + Lomb Inc, Dompé, Eyevance Pharmaceuticals LLC, Kala Pharmaceuticals, Mallinckrodt Pharmaceuticals, Neurolens, Osmotica Pharmaceuticals, Sun Pharmaceutical Industries Ltd
Deborah Reissman, PharmD
CONSULTANT OR PAID ADVISORY BOARD MEMBER:
Market research interviews on dry eye disease (blinded)
HONORARIA:
Market research interviews on dry eye disease (blinded)
Jeffrey D. Dunn, PharmD, MBA, and Mary Elizabeth Meske, PharmD, RPh, report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.
Articles in this issue
over 5 years ago
Evolving Knowledge of the Unmet Needs in Dry Eye DiseaseAdvertisement
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
FDA Approves Atacicept for IgA Nephropathy
3
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs
4
Quest Adds Haystack MRD to OncoEMR for Community Oncology
5

